INFORMATION DISCLOSURE STATEMENT

Applicant : Gadde, et al.

App. No : 10/830,071

Filed : April 23, 2004

For : METHOD FOR TREATING OBESITY

Examiner : Marschel, Ardin H.

Art Unit : 1614

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 45 references to be considered by the Examiner. Also enclosed are 26 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 26 April 2007

By: New . Wallon Joseph J. Mallon

Registration No. 39,287 Attorney of Record Customer No. 20,995 (619) 235-8550

3690326 042407

OREX.009C1

Attorney Docket No.

SHEET 1 OF 3

			U.S. PATENT	DOCUMENTS	
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevan Figures Appear
	1	4,855,306	08-08-1989	Markstein, et al.	
	2	5,312,925	05-17-1994	Allen, et al.	
	3	5,403,595	04-01-1995	Kitchell, et al.	
	4	5,486,362	01-01-1996	Kitchell	
	5	6,150,366	11-21-2000	Arenson, et al.	
	6	6,197,827	03-01-2001	Cary	
	7	6,210,716	04-01-2001	Chen et al.	
	8	6,245,766 B1	06-12-2001	Watsky, Eric	
	9	6,248,363	06-19-2001	Mahesh, et al.	
	10	6,274,579	08-14-2001	Morgan et al.	
		6,686,337	02-03-2004	Gregory S. Connor	
		6,713,488	03-30-2004	Sadee, et al.	
		6,905,708	06-14-2005	Li, et al.	
	14	7,109,198	09-19-2006	Gadde, et al.	
	15	2002-0025972	2/28/2002	Hintz, Martin C.	
	16	2002-0037836	03-28-2002	Henriksen	
	17	2003-0144271	7-0-2003	Shulman	
	18	2004-0198668	10-07-2004	Gadde, et al.	
	19	2004-0242974	12-00-2004	Glover	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	т¹
	20	WO 90/13294	11-15-1990	Whitby Research, Inc.		
	21	WO 04/050020	06-17-2004	Simon		
	22	WO 04/110368	12-23-2004	Merck & Co.		
	23	WO 04/110375	12-23-2004	Merck & Co.		
	24	WO 05/000217	01-06-2005	Merck & Co.		
	25	RU 2214241 (English abstract)	06-28-1996	Orto-MakneJL Farmas' Jutikal, Ink		

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

		P10/St
	Application No.	10/830,071
INFORMATION DISCLOSURE	Filing Date	April 23, 2004
STATEMENT BY APPLICANT	First Named Inventor	Gadde, Kishore M.
STATEMENT BY AFFLICANT	Art Unit	1614
(Multiple sheets used when necessary)	Examiner	Marschel, Ardin H.
CHEET 2 OF 2	Attempt Docket No.	ODEN 000C1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serali, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	26	Aronne, et al. "Weight Gain in the Treatment of Mood Disorders"; J Clin Psychiatry 2003;64 (supple 8)	
	27	Berke, et al., "Medical Management of Obesity", American Academy of Family Physicians, 2000 Jul 15;62(2):419-26 ABSTRACT	
	28	BLANCHARD, et al., "Pancreatitis Treated with Didanosine and Tenofabir Disoproxii Fumarate" Clinical Infectious Diseases, 2003;37 pgs 57-62	
	29	Carpenter, et al. "Mirtazapine Augmentation in the Treatment of Refractory Depression"; J Clin Psychiatry 60:1, January 1999	
	30	Cash, et al. "Attitudes about antidepressants: Influence of information about weight-related side effects"; Perceptual and Motor Skills, 2000, 90, 453-456	
	31	Deshmukh, et al. "Managing weight gain as a side effect of antidepressant therapy"; Cleveland Clinic Journal or Medicine Vol. 70, 7 July 2003	
	32	Fava, Maurizio. "Weight Gain and Antidepresants"; J Clin Psychiatry 2000;61 (suppl 11)	
	33	FUKAGAWA et al., "Monoaminergic anorectic agents", Nippon Yikurigaku Zasshi, 2001 Nov;118(5):303-8, 2001 ABSTRACT	
	34	Gehlert D.R., et al., "The Selective Norepinephrine Reuptake Inhibitor, LY368975, Reduces Food Consumption in Animal Models of Feeding", J. Pharmacology and Experimental Therapeutics 1998 [Oct;287(1):122-7 ABATRACT	
	35	Hashiguti, et al. "Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis"; Journal of Neural Transmission (1993) 93:213-223	
	36	Kanba et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry, 18(4), 707-715 (1994)	
	37	Kossard, et al. Defining Urticarial Dermatitis; Arch Dermatol/Vol. 142, Jan 2006	
	38	Malhotra, et al., "Medical Management of Obesity Associated With Mental Disorders", Journal or Clinical Psychiatry 2002;63[suppl 4]:24-32	
	39	Michelson, et al., "Aomexetine in the Treatment of Children and Adolescents with Attention Deficit/hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study", Pediatrics 2001 Nov;108(5):E83 ABSTRACT	
	40	Okada, et al. "Effects of zonisamide on extracellular levels of monoamine and its metabolite, and on Ca2+ dependent dopamine release" Epilepsy Research, 13 (1992) 113-119	
	41	Okada, et al. "Effects of zonisamide on dopaminergic system"; Epilepsy Research 22 (1995) 193-205	
	42	Olsen, et al., "Conjugate Addition Ligands of Opioid Antagonists. Methacrylate Esters and Ethers of 6Alpha-And 8Beta-Naltrexol", Journal of Medicinal Chemistry, American Chemical Society, vol. 33:2, 1990, 737-741	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conform in conformance and not considered. Include copy of this form with next community to the control of the c	

T¹ - Place a check mark in this area when an English language Translation is attached.

		PTO/SB/08 Equivalent
	Application No.	10/830,071
INFORMATION DISCLOSURE	Filing Date	April 23, 2004
STATEMENT BY APPLICANT	First Named Inventor	Gadde, Kishore M.
STATEMENT BY AFFEIGANT	Art Unit	1614
(Multiple sheets used when necessary)	Examiner	Marschel, Ardin H.
SHEET 3 OF 3	Attorney Docket No.	OREX.009C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	43	Stromberg, et al., "A comparison of the effects of 6-beta nattrexol and nattrexone on the consumption of ehanol or sucrose using a limited-access procedure in rats." Pharmacology, Biochemistry, and Behavior, vol. 72, 483-490 (2002)	
	44	Tollefson, et al., Am J. Psychiatry, 154(5), 457-465 (1997)	
	45	Wilner, "Is Weight Loss With Zonisamide Gender-Specific?", Dr. Tran, 2002 Annual Meeting of the American Epilepsy Society	

3681907 042307

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.